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ABSTRACT 
By employing recently published structure-based virtual screening (SBVS) to identify potent 
cyclooxygenase-2 (COX-2) inhibitors, all isoflavones collected by ZINC15 database were 
virtually screened. There were 3371 isoflavones in ZINC15 database and 1356 compounds out of 
them met the Lipinski’s rule of 5. Notably, only three isoflavones out of those 1356 compounds 
were identified as potent COX-2 inhibitors. 
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ABSTRAK 
Telah dilakukan penapisan virtual berbasis struktur pada seluruh isoflavone yang dikoleksi 
oleh basis data ZINC15 dengan memanfaatkan protokol yang sudah divalidasi secara 
retrospektif. Pada basis data ZINC15 didapati ada 3371 isoflavon dengan 1356 yang memenuhi 
Lipinski’s rule of 5. Dari 1356 isoflavon tersebut hanya 3 yang teridentifikasi sebagai inhibitor 
poten untuk siklooksigenase-2. 
Kata kunci: penapisan virtual, isoflavon, basis data ZINC15, siklooksigenase-2 
 
 
 
INTRODUCTION 
Computational medicinal chemistry 
tools especially structure-based virtual 
screening (SBVS) campaigns have become a 
routine of work in drug discovery (Chen, 
2015; Weiss et al., 2016). Recently, an SBVS 
protocol to identify potent cyclooxygenase-2 
has just published (Istyastono, 2017). The 
protocol uses PLANT1.2 docking software 
(Korb et al., 2009, 2007), PyPLIF (Radifar et 
al., 2013a, 2013b), and the best decision tree 
resulted from binary quantitative structure-
activity analysis of the results in retrospective 
validation using DUD-E (Mysinger et al., 
2012). Compared to previously published 
SBVS protocols (Huang et al., 2006; 
Istyastono, 2016; Krüger and Evers, 2010; 
Mysinger et al., 2012; Yuniarti et al., 2011), 
this protocol shows better predictive ability 
with enrichment factor (EF) value of 273.166 
(Istyastono, 2017). The SBVS protocol with 
substantially better predictive ability offers 
opportunities to efficiently discover novel 
inhibitors for cyclooxygenase-2 (COX-2). 
Isoflavones are very well known as 
phytoestrogens and correlated to breast cancer 
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due to their estrogenic activities (Dixon, 2004; 
Helferich et al., 2008; Varinska et al., 2015). 
Nevertheless, a selective COX-2 inhibitor 
celecoxib was reported having estrogenic 
activity by binding to estrogen receptor alpha 
(Istyastono et al., 2015), which indicates that 
there are some similarities in the ligand 
binding to COX-2 and to estrogen receptor 
alpha. Therefore, the other way around, it is of 
considerable interest to identify novel potent 
COX-2 inhibitors by screening on isoflavones. 
The research presented in this article 
aimed to discover isoflavones as novel potent 
COX-2 inhibitors. The SBVS protocol 
constructed and retrospectively validated by 
Istyastono (2017) to identify potent COX-2 
inhibitors were employed to virtually screen 
isoflavones collected in the ZINC15 database 
(Sterling and Irwin, 2015). Three isoflavones 
were identified in the research presented in 
this article. 
 
METHODS 
Materials 
Main materials used in this research are 
the compounds collected in ZINC15 database, 
which could be accessed in 
http://zinc15.docking.org/ (Sterling and Irwin, 
2015). Only compounds with isoflavone 
substructure (Figure 1) were selected. The 
compounds were downloaded in the SMILE 
formats and subsequently subjected to SBVS 
protocol to identify potent COX-2 inhibitors 
developed by Istyastono (2017). 
 
Instrumentations 
Similar to Istyastono (2017), all 
computation were performed on a Linux 
(Ubuntu 10.04 LTS Lucid Lynx) machine with 
Intel(R) Xeon(R) CPU E3-1220 as the 
processors (Quad-Core @ 3.10 GHz) and 8.00 
GB of RAM. The applications employed in 
this research were SPORES (ten Brink and 
Exner, 2009), PLANTS1.2 (Korb et al., 2009, 
2007), Open Babel 2.2.3 (O’Boyle et al., 
2011), and PyPLIF 0.1.1 (Radifar et al., 
2013b).  
Procedures 
Ligand Preparation 
In the drawing module in the ZINC15 
database website (http://zinc15.docking.org 
/substances/home/), isoflavone (Figure 1) was 
built and subsequently the button 
“Substructure” was clicked. All listed 
compounds were then downloaded in their 
SMILES format. Subsequently, the 
downloaded compounds were filtered using --
filter module in OpenBabel to select only 
compounds that meet the Lipinski’s rule of 
five (Lipinski et al., 2001), for example by 
using the following script: “obabel -ismi 
splitted/isoflavone.$i.smi -osdf -O temp.sdf --
gen2d | obabel -isdf temp.sdf -osmi --filter 
"HBD<5 HBA1<10 MW<500 logP<5" > 
filtered_lipinski-ro5/np.$i.smi”. All remaining 
compounds were then subjected in the ligand 
preparation process as described in Istyastono 
(2017). 
 
Virtual Screening Campaign 
All prepared ligands in three-
dimensional form and mol2 formats resulted in 
the previous section were subjected to 
molecular docking simulations for five times 
independently using PLANTS1.2 and the 
protein-ligand interactions of all docked poses 
were identified and the ensPLIF values were 
calculated (Istyastono, 2017). Based on the 
ensPLIF values resulted in this research and 
the decision tree presented in Figure 1 in 
(Istyastono, 2017), the potent COX-2 
inhibitors were identified. 
 
 
Figure 1. Isoflavone structure 
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ZINC000072054435 
 
ZINC000149610875 
 
 
ZINC000034194055/CHEMBL1290567 
 
Figure 2. Identified potent COX-2 inhibitors 
 
 
RESULTS AND DISCUSSION 
The ZINC15 database contains over 100 
million purchasable compounds (Sterling and 
Irwin, 2015). Notably, there were 3371 
compounds containing an isoflavone 
substructure (Figure 1) could be downloaded 
from the ZINC15 database. By employing --
filter module in OpenBabel (O’Boyle et al., 
2011), the isoflavones in the ZINC15 database 
were filtered and 1356 out of them that passed 
the filtering using the Lipinski’s rule of 5.  
By employing retrospectively validated 
SBVS protocol to identify potent COX-2 
inhibitors (Istyastono, 2017), all remaining 
compounds were virtual screened. It had been 
expected that there would be many isoflavones 
identified as potent COX-2 inhibitors due to 
the fact that a selective COX-2 inhibitors 
celecoxib showed potent inhibition toward 
estrogen receptor alpha (Istyastono et al., 
2015). However, only three isoflavones were 
identified as potent COX-2 inhibitors (Figure 
2). Therefore, the idea about similarities 
between binding pocket of COX-2 and 
estrogen receptor alpha (Istyastono, 2017) 
should be revisited. 
Notably, one out of three identified 
potent inhibitors for COX-2 
(ZINC000034194055) could also be found in 
the ChEMBL database as CHEMBL1290567 
(Bento et al., 2014). The compound was 
reported having activity as an antioxidant 
(Mitra et al., 2010). The activity of this 
compound as COX-2 inhibitor should be 
verified in vitro, which could also be used for 
external validation.   
 
CONCLUSION 
Three isoflavones in the ZINC15 
database were identified as potent COX-2 
inhibitors in SBVS campaigns using 
retrospectively validated protocol by 
Istyastono (2017). Further in vitro verification 
is required to establish the activity of those 
compounds as COX-2 inhibitors. Priority 
should be given to ZINC000034194055 
(CHEMBL1290567) which was also reported 
as an antioxidant. 
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